Publication Date




Download Full Text (925 KB)


Antimicrobial therapy is essential to treat cystic fibrosis (CF) lung infections. Empiric antimicrobial selection is generally based on previous culture information and, if available, an institution-specific antibiogram (ABGM). Most institutions antibiograms exclude cultures from individuals with cystic fibrosis, imposing challenges with empiric antimicrobial selection and monitoring susceptibility patterns over time. A cystic fibrosis-specific antibiogram may help drive population-specific antimicrobial selection and improve antimicrobial stewardship.


Infectious Disease | Pathology | Pharmacy and Pharmaceutical Sciences | Pulmonology


Presented at the 34th Annual North American Cystic Fibrosis Conference, in Philadelphia, PA, October 7-23, 2020.

Development and Interim Analysis of a Cystic Fibrosis-Specific Antibiogram



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.